In CMS5 inoculated control, Tregs increased the expressions of CD39, CTLA4, and latency-associated protein (LAP) 7 days post tumor challenge, suggesting the enhanced suppressive function of Tregs. The gene discussed is TGFB1; the disease is neoplasm.